Fatigue heralding multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1526-1532

  Berger, Joseph R ^a   Pocoski, Jennifer ^b   Preblick, Ronald ^a   Boklage, Susan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b BAYER CORPORATION   (United States)

Author keywords

chronic; epidemiology; fatigue; fatigue syndrome; malaise; multiple sclerosis; quality of life

Indexed keywords

4 AMINOPYRIDINE; ARMODAFINIL; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; METHYLPHENIDATE; MODAFINIL;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC FATIGUE SYNDROME; DIZZINESS; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEURALGIA; NEWBORN; OUTCOME ASSESSMENT; PARALYSIS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRESCRIPTION; RISK ASSESSMENT; SCHOOL CHILD; SKIN SENSATION; SPEECH DISORDER; TRIGEMINUS NEURALGIA; VERTIGO;

CHRONIC; EPIDEMIOLOGY; FATIGUE; FATIGUE SYNDROME; MALAISE; MULTIPLE SCLEROSIS; QUALITY OF LIFE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84876265399     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513477924     Document Type: Article

References (21)

1. Amato MP, Ponziani G, Rossi F, et al. Quality of life in multiple sclerosis: The impact of depression, fatigue and disability. Mult Scler. 2001 ; 7: 340-344
2. Junghaenel DU, Christodoulou C, Lai JS, et al. Demographic correlates of fatigue in the US general population: results from the patient-reported outcomes measurement information system (PROMIS) initiative. J Psychosom Res. 2011 ; 71: 117-123
3. Comi G, Leocani L, Rossi P, et al. Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol. 2001 ; 248: 174-179
4. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984 ; 65: 135-138
5. Bergamaschi R, Romani A, Versino M, et al. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol. 1997 ; 12: 247-251
6. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994 ; 21: 9-14
7. Packer TL, Sauriol A, Brouwer B. Fatigue secondary to chronic illness: Postpolio syndrome, chronic fatigue syndrome, and multiple sclerosis. Arch Phys Med Rehabil. 1994 ; 75: 1122-1126
8. van der Werf SP, Jongen PJ, Lycklama A, Nijeholt GJ, et al. Fatigue in multiple sclerosis: Interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. J Neurol Sci. 1998 ; 160: 164-170
9. Bakshi R. Fatigue associated with multiple sclerosis: Diagnosis, impact and management. Mult Scler. 2003 ; 9: 219-227
10. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. J Neurol Sci. 2002 ; 205: 51-58
11. Taphoorn MJ, van Someren E, Snoek FJ, et al. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. J Neurol. 1993 ; 240: 446-448
12. Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. Arch Neurol. 1988 ; 45: 435-437
13. Bates DW, Schmitt W, Buchwald D, et al. Prevalence of fatigue and chronic fatigue syndrome in a primary care practice. Arch Intern Med. 1993 ; 153: 2759-2765
14. Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999 ; 159: 2129-2137
15. Steele L, Dobbins JG, Fukuda K, et al. The epidemiology of chronic fatigue in San Francisco. Am J Med. 1998 ; 105: 83S - 90S
16. Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010 ; 16: 703-712
17. White LA, Robinson RL, Yu AP, et al. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain. 2009 ; 10: 976-983
18. Nag SS, Daniel GW, Bullano MF, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm. 2007 ; 13: 652-663
19. Romley J, Goldman D, Eber M, et al. Cost-sharing and initiation of disease-modifying therapy for multiple sclerosis. Am J Manag Care. 2012 ; 18: 460-464
20. Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: A retrospective cohort study. BMC Neurol. 2011 ; 11: 122
21. Marrie RA, Yu N, Blanchard J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010 ; 74: 465-471